TrialEuropean urology2019

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Ethan M Basch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.